Updated:
Farmak
Farmak, Ukraine's top drug maker since 2010, exports to 50+ countries and reinvests 90% of profit into R&D and manufacturing.
Farmak
Farmak operates as an independent pharmaceutical manufacturer rather than a family office, though it is associated with the Zhebrivsky family through a charitable foundation. The company has held the top position on Ukraine's drug market by sales volume since 2010, according to Proxima Research's 2024 data. It produces over 250 drug names and launches up to 20 new products annually. The company operates two factories in Kyiv and Shostka, plus a sterile injectables plant in Barcelona launched in 2025. Farmak maintains a full production cycle from API synthesis to finished dosage forms, with 26 production lines. Its R&D complex includes 12 laboratories and employs 150 scientists, including 40 PhDs. The company invests roughly $15 million annually in research, with partnerships spanning 50+ global institutions. Farmak exports to more than 50 countries across Europe, Central Asia, the Middle East, Southeast Asia, and Africa. The group employs about 3,000 people. Besides its Ukrainian hubs, Farmak runs subsidiaries in Switzerland, the UK, Poland, the Czech Republic, Slovakia, Spain, and representative offices in Uzbekistan, Kazakhstan, Kyrgyzstan, Moldova, Vietnam, and the UAE. The Zhebrivsky Family Charitable Foundation operates separately, focusing on military aid and social support. In mid-2025, the foundation reported donating 1.7 million UAH for medicines for Ukrainian soldiers. Farmak is a private operating business, not a capital allocator — it manufactures and sells pharmaceuticals. Its structural distinctiveness lies in its vertical integration: it controls API synthesis, finished-dose manufacturing, and global distribution, while maintaining European GMP certifications across all facilities. The full ownership structure and wealth-origin details of the Zhebrivsky family are not publicly disclosed.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Ukraine
City
Kyiv
Corporate office
Kyiv, Ukraine
Additional offices
Baar, Switzerland · Tashkent, Uzbekistan · Almaty, Kazakhstan · Bishkek, Kyrgyzstan · Chișinău, Moldova · Dubai, United Arab Emirates · Ho Chi Minh City, Vietnam · Warsaw, Poland · Bratislava, Slovakia · Prague, Czech Republic · Hull, United Kingdom · Barcelona, Spain
Sector focus
Frequently asked questions
Who owns Farmak?
Farmak is a private Ukrainian pharmaceutical company. The Zhebrivsky family is associated with the company through the Zhebrivsky Family Charitable Foundation, but public ownership details and the wealth origin of the family are not disclosed.
Is Farmak structured as a family office?
No. Farmak is an operating pharmaceutical manufacturer, not a family office. It does not manage third-party capital or make external investment allocations. The Zhebrivsky family maintains a separate charitable foundation for philanthropic activities.
What investment stages or asset classes does Farmak participate in?
Farmak is not an investment firm. It operates exclusively in pharmaceutical manufacturing, R&D, and distribution. Its capital deployment is internal: reinvesting up to 90% of profit into production capacity, R&D, and regulatory compliance (per the firm's website).
What markets does Farmak serve?
Farmak leads the Ukrainian pharmaceutical market by sales volume and exports to over 50 countries. Key regions include Europe (Poland, Slovakia, Czech Republic, UK, Spain, Switzerland), Central Asia (Kazakhstan, Uzbekistan, Kyrgyzstan), the Middle East (UAE), and Southeast Asia (Vietnam), with additional offices in Moldova (per the firm, 2025).
What is the Zhebrivsky Family Charitable Foundation?
The Zhebrivsky Family Charitable Foundation is a separate philanthropic entity associated with the owners of Farmak. It conducts social and military support activities, such as donating medicines for Ukrainian soldiers. The foundation is operationally independent from the manufacturing business.
What regulatory certifications does Farmak hold?
Farmak's production facilities and labs hold European GMP certifications and have passed nearly 100 national and foreign inspections from partners in the UK, Switzerland, Germany, and other countries. Its quality control laboratories are accredited for 144 testing methods listed in the Ukrainian, European, British, and US Pharmacopoeias.
Does Farmak have any known relationship with external family offices or allocators?
No publicly available information suggests any relationship with external family offices, institutional allocators, or third-party capital vehicles. The company operates as a private, self-funded pharmaceutical manufacturer.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: